eprintid: 10196640
rev_number: 6
eprint_status: archive
userid: 699
dir: disk0/10/19/66/40
datestamp: 2024-09-04 14:57:34
lastmod: 2024-09-04 14:57:34
status_changed: 2024-09-04 14:57:34
type: working_paper
metadata_visibility: show
sword_depositor: 699
creators_name: Williams-Eliyesil, Sion
title: Vaccine development as a public service: Public service logic in the development of the Oxford AstraZeneca COVID-19
vaccine
ispublished: pub
divisions: UCL
divisions: B04
divisions: F49
note: This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: This paper examines the development of the Oxford AstraZeneca vaccine during the COVID-19
pandemic as a paradigmatic example of an effective public-private partnership and groundbreaking innovation in drug development. Central to this successful approach was the Vaccine
Taskforce (VTF), a novel state entity which distinguished itself by taking responsibility for the
outcome of the vaccine development process, necessitating an active role in the process. In
this paper, the development of the Oxford AstraZeneca vaccine is reimagined as a new public
service delivered by the VTF, identifying the important role of public service logic (PSL) in the
design and delivery of the vaccine. Accordingly, the paper employs service design blueprinting,
a common technique used in the design of public services, as an analytical framework.
Blueprinting enables a comprehensive analysis of the resources and expertise mobilised by
both public and private actors, documents the highly innovative process that enabled the
fastest vaccine development in history, and materialises the unique role that the state played
in maintaining an essential connective tissue between all parties to enable the mindset that
underpinned success. The results of the service blueprinting highlight that the state can play a
broader role in drug development, moving beyond facilitating private actors and becoming an
active participant in the innovation process, further suggesting that the engagement of PSL
with existing innovation commons can shape the motivations of private actors in the creation of
public value. Extending the design lens, the paper concludes by examining the question: how
might we see the development of new drugs as a public service?
date: 2024-06-25
publisher: UCL Institute for Innovation and Public Purpose
official_url: https://www.ucl.ac.uk/bartlett/public-purpose/publications/2024/jun/vaccine-development-public-service
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2309753
lyricists_name: Williams-Eliyesil, Sion
lyricists_id: SSWIL12
actors_name: Williams-Eliyesil, Sion
actors_name: Kaltenbacher, Brigitte G
actors_id: SSWIL12
actors_id: BGKAL87
actors_role: owner
actors_role: impersonator
full_text_status: public
series: Working Paper Series (IIPP WP 2024-08)
place_of_pub: London, UK
pages: 27
issn: 2635-0122
citation:        Williams-Eliyesil, Sion;      (2024)    Vaccine development as a public service: Public service logic in the development of the Oxford AstraZeneca COVID-19 vaccine.                    (Working Paper Series (IIPP WP 2024-08) ). UCL Institute for Innovation and Public Purpose: London, UK.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10196640/1/Williams-Eliyesil_iipp_working_paper_2024-08.pdf